Cart
sales@molnova.com
(9Z,12Z)-N-(3-Methoxybenzyl)octadeca-9,12-dienamide
CAS No. 883715-22-8
(9Z,12Z)-N-(3-Methoxybenzyl)octadeca-9,12-dienamide( —— )
Catalog No. M31463 CAS No. 883715-22-8
N-(3-Methoxybenzyl-(9z,12z)-octadecadienamide is a Macamide impurity that may be used in the study of metabolic diseases.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 29 | In Stock |
|
| 10MG | 32 | In Stock |
|
| 25MG | 57 | In Stock |
|
| 50MG | 73 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product Name(9Z,12Z)-N-(3-Methoxybenzyl)octadeca-9,12-dienamide
-
NoteResearch use only, not for human use.
-
Brief DescriptionN-(3-Methoxybenzyl-(9z,12z)-octadecadienamide is a Macamide impurity that may be used in the study of metabolic diseases.
-
DescriptionN-(3-Methoxybenzyl-(9z,12z)-octadecadienamide is a Macamide impurity that may be used in the study of metabolic diseases.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number883715-22-8
-
Formula Weight399.6
-
Molecular FormulaC26H41NO2
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
[D-Trp11]-Neurotensi...
[D-Trp11]-Neurotensin, an analogue of Neurotensin (NT), is a selective antagonist of NT in perfused rat hearts but behaves as a full agonist in guinea pig atria and rat stomach strips. [D-Trp11]-Neurotensin can inhibit NT-induced hypotension.
-
novaluron
Novaluron is a?benzoylurea?insecticide a member of monochlorobenzenes an aromatic ether and an organofluorine compound.
-
Stachydrine Hydrochl...
Stachydrine Hydrochloride is an effective component that mainly extracted from the leaf of Leonurussibiricus.
